ALKERMES PLC's ticker is ALKS and the CUSIP is G01767105. A total of 257 filers reported holding ALKERMES PLC in Q2 2017. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $151,000 | +22.8% | 7,400 | +17.5% | 0.03% | -6.2% |
| Q3 2019 | $123,000 | +59.7% | 6,300 | +85.3% | 0.03% | +45.5% |
| Q2 2019 | $77,000 | -75.8% | 3,400 | -61.8% | 0.02% | -48.8% |
| Q1 2019 | $318,000 | +44.5% | 8,910 | +15.5% | 0.04% | -39.4% |
| Q4 2018 | $220,000 | +464.1% | 7,712 | +756.9% | 0.07% | +914.3% |
| Q3 2018 | $39,000 | -83.3% | 900 | -84.2% | 0.01% | -86.8% |
| Q2 2018 | $233,000 | +2230.0% | 5,700 | +2750.0% | 0.05% | +2550.0% |
| Q3 2017 | $10,000 | -94.3% | 200 | -93.3% | 0.00% | -90.0% |
| Q1 2017 | $176,000 | -72.3% | 3,000 | -77.8% | 0.02% | -75.6% |
| Q3 2016 | $635,000 | +126.0% | 13,500 | +107.7% | 0.08% | +110.3% |
| Q2 2016 | $281,000 | -74.2% | 6,500 | -65.1% | 0.04% | -68.8% |
| Q3 2015 | $1,091,000 | +51.3% | 18,600 | +66.1% | 0.12% | +28.9% |
| Q2 2015 | $721,000 | – | 11,200 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 14,040,000 | $313,513,000 | 35.43% |
| Krensavage Asset Management, LLC | 1,411,682 | $31,523,000 | 10.04% |
| Prosight Management, LP | 502,150 | $11,213,000 | 6.01% |
| Hardman Johnston Global Advisors LLC | 5,734,259 | $128,046,000 | 5.76% |
| 13D Management LLC | 415,055 | $9,268,000 | 4.85% |
| Ally Bridge Group (NY) LLC | 300,000 | $6,699,000 | 4.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 593,000 | $13,248,000 | 4.25% |
| GREAT POINT PARTNERS LLC | 507,500 | $11,332,000 | 2.73% |
| Tamarack Advisers, LP | 200,000 | $4,466,000 | 2.62% |
| Zebra Capital Management LLC | 22,134 | $494,000 | 1.88% |